ILA — Island Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- AU$123.95m
- AU$116.70m
- AU$0.06m
Annual income statement for Island Pharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0.011 | 0.005 | 0.059 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.14 | 2.81 | 2.91 | 2.86 | 3.96 |
| Operating Profit | -2.14 | -2.81 | -2.9 | -2.86 | -3.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.13 | -2.61 | -2.83 | -2.86 | -3.92 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.13 | -2.61 | -2.83 | -2.86 | -3.92 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.13 | -2.61 | -2.83 | -2.86 | -3.92 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.13 | -2.61 | -2.83 | -2.86 | -3.92 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.023 | -0.029 | -0.031 | -0.032 | -0.023 |